- Featured Product
- KD/KO Validated
BRCA2 Polyclonal antibody
BRCA2 Polyclonal Antibody for ELISA
验证数据展示
产品信息
19791-1-AP targets BRCA2 in WB, IHC, ELISA applications and shows reactivity with human samples.
| Tested Applications | ELISA Application Description |
| Cited Applications | WB, IHC |
| Tested Reactivity | human |
| Cited Reactivity | human |
| Immunogen | Peptide 种属同源性预测 |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Full Name | breast cancer 2, early onset |
| Synonyms | BRCA2, BRCC2, breast cancer 2, early onset, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1 |
| Calculated Molecular Weight | 384 kDa |
| GenBank Accession Number | NM_000059 |
| Gene Symbol | BRCA2 |
| Gene ID (NCBI) | 675 |
| RRID | AB_10638915 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P51587 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
BRCA2, also named as FACD and FANCD1, is involved in double-strand break repair and/or homologous recombination. BRCA2 may participate in S phase checkpoint activation. Defects in BRCA2 are a cause of genetic susceptibility to breast cancer (BC) which also called susceptibility to familial breast-ovarian cancer type 2 (BROVCA2).
实验方案
| Product Specific Protocols | |
|---|---|
| WB protocol for BRCA2 antibody 19791-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
发表文章
| Species | Application | Title |
|---|---|---|
Nucleic Acids Res LncRNA lnc-RI regulates homologous recombination repair of DNA double-strand breaks by stabilizing RAD51 mRNA as a competitive endogenous RNA. | ||
Int J Biol Macromol Antitumor efficacy of a recombinant EGFR-targeted fusion protein conjugate that induces telomere shortening and telomerase downregulation | ||
Elife LIN37-DREAM prevents DNA end resection and homologous recombination at DNA double-strand breaks in quiescent cells | ||
J Med Chem Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA | ||
Pharmacol Res FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. | ||
Mol Cancer The negative interplay between Aurora A/B and BRCA1/2 controls cancer cell growth and tumorigenesis via distinct regulation of cell cycle progression, cytokinesis, and tetraploidy.
|
